Compare EPRT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPRT | RYTM |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.8B |
| IPO Year | 2018 | 2017 |
| Metric | EPRT | RYTM |
|---|---|---|
| Price | $32.43 | $101.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $36.79 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.6M | 872.9K |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | 11.30 | ★ 28.34 |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $561,219,000.00 | N/A |
| Revenue This Year | $17.12 | $55.34 |
| Revenue Next Year | $16.27 | $86.06 |
| P/E Ratio | $116.64 | ★ N/A |
| Revenue Growth | ★ 24.82 | N/A |
| 52 Week Low | $28.95 | $74.50 |
| 52 Week High | $34.73 | $122.20 |
| Indicator | EPRT | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 44.52 |
| Support Level | $29.27 | $98.30 |
| Resistance Level | $33.60 | $113.51 |
| Average True Range (ATR) | 0.59 | 3.77 |
| MACD | 0.18 | -1.71 |
| Stochastic Oscillator | 64.58 | 4.62 |
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses. The Company generally invests in and leases freestanding, single-tenant commercial real estate facilities where a tenant services its customers and conducts activities that are essential to the generation of the tenant's sales and profits.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.